Image 2-Retevmo (selpercatinib) - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers

Image 2-Retevmo (selpercatinib)
Retevmo is a potent and selective RET kinase inhibitor. Credit: Eli Lilly and Company.